AMPLY Discovery is a UK biotech turning the 98% of the genome largely ignored by drug developers into a pipeline of first-in-class therapeutics. Six AI engines. Two wet labs. One closed loop between silicon and bench.
We've just announced a strategic investment from Keeps Biomed (Keeps Biopharma, South Korea) and a partnership to explore oncology collaboration — plus we've appointed Oliver Rausch as AMPLY's new CSO.
These are pivotal moments in AMPLY Discovery's nascent development: our approach is moving from interesting towards partner-ready — mining multi-omic data (including non-coding regions of the genome) and backing it up with iterative wet-lab validation so our partners can make real go/no-go decisions. AI as the product isn't the focus for AMPLY — we believe that the techbio winners will eventually be the teams that can turn computation into credible, experimentally validated programmes with clear translational logic.
This key hire of Oliver and this partnership put AMPLY in an incredible position to eventually be one of those next winners.
Each engine is a specialised tool that solves one part of the dark-genome problem — from finding the right target, to designing the molecule, to deciding what runs next at the bench.
Together, they form an integrated ML-discovery loop called TALON.
… in two world-class translational hubs. Continuously teaching the platform…
… so we can tackle critical diseases like Triple-Negative Breast Cancer and Multi-Drug-Resistant Tuberculosis.
Two antimicrobial-peptide programmes targeting drug-resistant respiratory infection. Two long non-coding RNA oligonucleotide programmes against hard-to-treat oncology indications.
Around half a million new MDR-TB cases emerge each year. First-line treatment failures push patients into multi-drug regimens lasting 9+ months with significant toxicity. Antimicrobial-peptide therapy offers a fundamentally different mechanism with low resistance liability, delivered directly to the site of infection via aerosol.
Stage · In VivoCystic fibrosis patients face chronic colonisation by Pseudomonas aeruginosa and resistant Staphylococcus species — pathogens against which conventional antibiotics are steadily losing ground. Inhaled peptide therapeutics deliver multi-mechanism activity at high local concentration, straight to the airways.
Stage · In VivoTNBC accounts for ~15–20% of breast cancers and lacks the three actionable receptors (HER2, ER, PR) that drive standard targeted therapies, leaving patients largely chemotherapy-dependent. Our oligos silence cancer-specific dependencies surfaced by HALLUX in the dark genome.
Stage · In Vitro POCAML carries a 5-year survival rate below 30% in older adults. Genetic heterogeneity and a thin pipeline of targeted options leave most patients reliant on intensive chemotherapy. Our platform surfaces subtype-specific lncRNA dependencies that open new therapeutic windows.
Stage · In Vitro POCAMPLY is led by operators with deep biotech, computational biology, and commercial experience — over 100 years combined across the founding management team and our scientific lead.
25+ years across financial asset management, predictive marketing, and computational biology. PhD in bioinformatics from Aberystwyth (2018), PDRA at QUB. Architect of the TALON platform.
25+ years of industry experience spanning technology licensing, corporate finance, and business development. Co-founded AMPLY out of Queen's University Belfast.